A bipartisan group of senators on March 18 sent a letter to the Food and Drug Administration urging the regulatory agency to provide further clarity and transparency in its policy regarding mobile medical applications. 

In the letter to FDA Commissioner Margaret Hamburg, the senators stated: “It is important for the FDA to be well-equipped with the proper tools to be able to advance public health while taking care that innovation is not stifled through uncertainty or over-regulation.”

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access